We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects.
- Authors
Beglinger, C; Poller, B; Arbit, E; Ganzoni, C; Gass, S; Gomez-Orellana, I; Drewe, J
- Abstract
This proof-of-concept study was performed in order to establish the pharmacokinetics and pharmacodynamics of increasing oral doses of the satiety peptides glucagon-like peptide-1 (GLP-1) and peptide YY3-36 (PYY3-36). Six healthy male subjects were given oral doses of either a placebo or GLP-1 in a dose-escalating schedule (doses of 0.5, 1.0, 2.0, and 4.0 mg). Next, another group of six healthy male subjects were given oral doses of either a placebo or PYY3-36 in the same pattern of escalating doses (doses of 0.25, 0.5, 1.0, 2.0, and 4.0 mg). In healthy male volunteers, (i) oral administration of either of the peptides induced a rapid and dose-dependent increase in plasma drug concentrations; (ii) oral administration of GLP-1 induced a potent effect on insulin release; and (iii) both peptides suppressed ghrelin secretion. In conclusion, this study showed, for the first time, that satiety peptides such as GLP-1 and PYY3-36 can be orally delivered safely and effectively in humans.Clinical Pharmacology & Therapeutics (2008); 84, 4, 468–474 doi:10.1038/clpt.2008.35
- Subjects
PHARMACOKINETICS; PHARMACODYNAMICS; PEPTIDES; PHARMACOLOGY; THERAPEUTICS
- Publication
Clinical Pharmacology & Therapeutics, 2008, Vol 84, Issue 4, p468
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1038/clpt.2008.35